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Background. Omega-3 (𝜔3) administration was shown to protect against hypoxic-ischemic injury. The objectives were to study
the neuroprotective effects of 𝜔3, in a model of global ischemia. Methods. Male Wistar rats were subjected to carotid occlusion
(30min), followed by reperfusion. The groups were SO, untreated ischemic and ischemic treated rats with 𝜔3 (5 and 10mg/kg, 7
days).The SO and untreated ischemic animals were orally treatedwith 1% cremophor and, 1 h after the last administration, theywere
behaviorally tested and euthanized for neurochemical (DA, DOPAC, and NE determinations), histological (Fluoro jade staining),
and immunohistochemical (TNF-alpha, COX-2 and iNOS) evaluations.The data were analyzed by ANOVA and Newman-Keuls as
the post hoc test. Results. Ischemia increased the locomotor activity and rearing behavior that were partly reversed by 𝜔3. Ischemia
decreased striatal DA and DOPAC contents and increased NE contents, effects reversed by 𝜔3. This drug protected hippocampal
neuron degeneration, as observed by Fluoro-Jade staining, and the increased immunostainings for TNF-alpha, COX-2, and iNOS
were partly or totally blocked by 𝜔3. Conclusion. This study showed a neuroprotective effect of 𝜔3, in great part due to its anti-
inflammatory properties, stimulating translational studies focusing on its use in clinic for stroke managing.
1. Background
Ischemic stroke is a pathologic condition and a major cause
of death and disability worldwide. Because of its huge socioe-
conomic burden and considering the global life expectancy
increases, one can assume that stroke is already the most
challenging disease [1]. Although animal stroke models have
shed light on the pathophysiology of ischemic stroke, the
translation of these results from bench to bedside has been
somewhat disappointing [2, 3].
Themost common cause of stroke is the sudden occlusion
of a blood vessel by a thrombus or embolism, resulting
in an almost immediate loss of oxygen and glucose to
the cerebral tissue. Brain is almost exclusively dependent
on the continuous steady flow of glucose and oxygen to
undergo oxidative phosphorylation for energy production,
since it has no energetic stores. Within minutes of vascular
occlusion, a complex sequence of pathophysiological events
called ischemic cascade occurs. The first consequence is the
depletion of substrates, particularly oxygen and glucose, that
causes the accumulation of lactate via anaerobic glycolysis.
Acidosis may enhance free-radical formation, interfering
with intracellular protein synthesis and worsening ischemic
brain injury [4, 5]. Energy failure leads to perturbation of the
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Na+/K+-ATPases and Ca2+/H-ATPases pumps and, in addi-
tion, the Na+-Ca2+ transporter is reversed [6]. Subsequently,
an alteration of ion homeostasis causes cytotoxic edema,
leading to events triggered by intracellular Ca2+ excess [1].
𝜔3 fatty acids are a group of essential fatty acids that serve
as energy substrates and integralmembrane components and,
therefore, play crucial roles in the maintenance of normal
neurological functions. Recent studies show that 𝜔3 fatty
acids display neuroprotective properties and may exert ben-
eficial effects on cerebral ischemia and other brain disorders
[7]. It is well recognized that cerebral ischemia induces exces-
sive release of excitatory amino acids, as glutamate and as-
partate, which provoke enzymatic processes leading to irre-
versible neuronal injury [8]. On the other hand, several
years ago, the behavioral effects of 𝜔3 fatty acids deficiency
were proposed to be mediated through monoaminergic
neurotransmission, including the dopaminergic system, what
was evidenced years later [9, 10].
Thus, the objectives of the present work were to study the
possible neuroprotective effects of 𝜔3 fatty acids in a model
of global brain ischemia in rats, focusing on behavior and
striatal DA, DOPAC, andNE levels. Besides, considering that
inflammation plays an important role in the pathogenesis of
ischemic stroke [11, 12] and the anti-inflammatory properties
of 𝜔3 [13–16] also observed by us [17], we decided to analyze
the action of 𝜔3 fatty acids on proinflammatory cytokines
and enzymes, in hippocampi from ischemic animals, through
TTC and Fluoro-Jade staining and with immunohistochem-
ical assays.
2. Material and Methods
2.1. Drugs and Reagents. Proepa (Ache´ Laborato´rios Far-
maceˆuticos SA) was the source of 𝜔3 fatty acids, while
sodium thiopental was from Laborato´rio Crista´lia, Brazil.
Cremophor EL, 2,3,5-triphenyltetrazolium chloride (TTC),
standard monoamines, and standard amino acids were from
Sigma-Aldrich, USA. All other reagents were of analytical
grade.
2.2. Animals. Male Wistar rats (200–250 g) were obtained
from the Animal House of the Faculty of Medicine Esta´cio
of Juazeiro do Norte, Brazil. The animals were housed at 24 ±
2∘C, under a 12 h light/12 h dark cycle and had free access to a
standard pellet diet (Purina chow) and tap water. They were
deprived of food for 8 h, before the experiments, except for
drinking water. The animals were treated in accordance with
the current law and the NIH Guide for the Care and Use of
Laboratory Animals. The project was previously approved by
the Animal’s Ethics Committee of the Faculty of Medicine of
the Federal University of Ceara´ at the city of Barbalha, Brazil.
2.3. Experimental Protocol. The animals were anesthetized
with sodium thiopental (50mg/kg, i.p.) and submitted to the
model of transitory global ischemia, by the bilateral occlusion
of both carotids, for 30min. After reperfusion, the incision
was sutured and the animals placed in individual plastic cages
for recovery, with water and food ad libitum. The sham-
operated groups (SO, controls) were submitted to the same
procedure, except for the clamping of the carotids. After
surgery, the animals were orally treated (by gavage) with
𝜔3 fatty acids, at the doses of 5 and 10mg/kg, daily for 7
days. The SO and ischemic groups received 1% Cremophor
(1mL/kg).The animals were distributed into 4 groups (except
for COX-2 immunostaining, where the 𝜔3 dose of 2.5mg/kg
was also used) as follows: SO, untreated ischemic, and
ischemic groups after treatments with 𝜔3 (5 and 10mg/kg,
p.o.). At the 7th day of treatment and 1 h after the last drug
administration, the animals were submitted to behavioral
tests (open field and water maze tests) and sacrificed for
striata dissection and hippocampal slicing. The striata were
used for homogenate preparations and DA, DOPAC, and
NE determinations. Hippocampal slices were processed for
immunohistochemistry assays.
2.4. Behavioral Testing
2.4.1. Open Field Test. This test is used to measure locomotor
activity in rodents and can also serve to determine motor
deficits and anxiety. It was originally described for the study
of emotionality in rats and now is one of the most popular
models in animal psychology [18]. Locomotor activity is
measured by determining the amount of distance traveled
and stereotyped behaviors, as rearing and grooming.The test
is sensitive to motor dysfunction, as well as hippocampal and
basal ganglia damage, and we used an arena (50×50×20 cm)
divided into four equal quadrants. Each animal was evaluated
for 5min, at the 7th day after ischemia, andwedetermined the
number of quadrants crossed by the animal with all 4 paws.
2.4.2.MorrisWaterMaze Test. This is a test of spatial learning
for rodents that relies on distal cues to navigate from start
locations around the perimeter of an open swimming arena
for locating a submerged escape platform. The original pro-
cedure was described as Morris water maze [19, 20]. Spatial
learning is assessed across repeated trials and reference
memory. The test has proven to be a robust and reliable
one and is strongly correlated with hippocampal synaptic
plasticity and NMDA receptor function. For that, we used
a circular black pool (1.7m of diameter and 1m height),
filled with water (0.59m deep), at 25∘C temperature. The
pool is divided into four quadrants and has a 10 cm diameter
platform immersed 0.5 cm below the water surface.The room
is provided with four cues located on North, South, East, and
West of the walls. The animals were subjected to two trials,
for two consecutive days (pretraining), and, 48 h after the
last trial, to the test in the water maze. The animals had a
maximum time of 54 s (cut-off time) for finding the platform,
where they can stay for 15 s but would have a second chance,
in case of failure.
2.4.3. Catecholamine Determinations by HPLC. For mea-
surements of dopamine (DA) and its metabolite (3,4-dihy-
droxyphenylacetic acid, DOPAC) as well as noradrenaline
(NE), striata from all groups were used to prepare 10%
homogenates. Homogenates were sonicated in 0.1M HClO
4
,
for 30 s, and centrifuged at 4∘C for 15min at 15,000 rpm,
and the supernatants were filtered (0.2 𝜇m, Millipore).
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Twenty-microliter samples were then injected into a high-
performance liquid chromatograph (HPLC) column. The
mobile phase was 0.163M citric acid, pH 3.0, containing
0.02mM EDTA with 0.69mM sodium octanesulfonic acid
(SOS), as an ion pairing reagent, 4% v/v acetonitrile, and 1.7%
v/v tetrahydrofuran. The monoamines were electrochemi-
cally detected, using an amperometric detector (Shimadzu,
Japan), by oxidation on a glassy carbon electrode at 0.85V
relative to the Ag-AgCl reference electrode. Their concentra-
tionswere determined by comparisonwith standards injected
into the HPLC column at the day of experiment and the
values expressed as ng/g tissue.
2.4.4. TTC Staining. TTC staining is considered a reliable
method for detection of cerebral infarction in rats after
ischemia [21]. The animals were decapitated and their brains
removed for TTC (2,3,5-triphenyltetrazolium chloride) stain-
ing. Then, 2mm coronal sections were obtained with the
rodent brain matrix apparatus (Harvard, USA). The slices
were incubated with TTC for 30min at 37∘C in the dark
and fixed by immersion in 4% buffered (7.4) formaldehyde
solution for 24 h. Afterwards, the sectionswere photographed
and ischemic areas were quantified by the Image J software
(NIH, USA). In those cells populations where the electron
mitochondrial transport is maintained, the TTC shows a red
color that is greatly decreased in brain ischemic areas.
2.4.5. Fluoro-Jade Staining. Fluoro-Jade is an anionic fluores-
cein derivative, used for the histological staining of neurons
which become fluorescent after degeneration. After paraffin
removal (by immersion in xylol), hippocampus sections
(5 𝜇m) were mounted on slides surrounded by gelatin and
rehydrated by immersion in ethanol for 3min, followed by
immersions in 70 and 50% ethanol solutions and distilled
water. The slices were placed into a 0.06% potassium per-
manganate solution, for 15min, washed in distilled water, and
transferred to a Fluoro-Jade solution where they stayed for
30min (with gentle stirring). After staining, the slices were
washed in distilled water (3 times, 2min each time). The
excess of water was discarded and the dry slices mounted
in Fluoromount media and examined with a fluorescence
microscope.The data were quantified by the Image J software
(NIH, USA).
2.4.6. Immunohistochemistry Assays for TNF-Alpha, COX-2,
and iNOS. Brain hippocampal sections were fixed in 10%
buffered formol, for 24 h, followed by a 70% alcohol solution
and embedded into paraffin wax for slices processing on
appropriate glass slides. These were placed into the oven
at 58∘C, for 10min, followed by deparaffinization in xylol,
rehydration in alcohol at decreasing concentrations, and
washing in distilled water and PBS (0.1M sodium phosphate
buffer, pH 7.2), for 10min. The endogenous peroxidase was
blocked with a 3% hydrogen peroxide solution, followed by
incubation with the appropriate primary anti-antibody for
TNF-alpha, iNOS, and COX-2, and diluted according to the
manufacturers’ instructions (Santa Cruz or Millipore, USA),
for 2 h, at room temperature in a moist chamber. The glass
slides were then washed with PBS (3 times, 5min each)
and incubated with the biotinylated secondary antibody, for
1 h, at room temperature in a moist chamber. Then, they
were washed again in PBS and incubated with streptavidin-
peroxidase, for 30min, at room temperature (in a moist
chamber) and, after a final wash in PBS, incubated in 0.1%
DAB solution (in 3% hydrogen peroxide). Finally, the glass
slides were washed in distilled water and counterstained with
Mayer’s hematoxylin, washed in tap water, dehydrated in
alcohol (at increasing concentrations), diaphonized in xylol,
andmounted on Entelan for optic microscopy examination.
The data were quantified by the Image J software (NIH,USA).
2.5. Statistical Analyses. The data are presented as means
± SEM and analyzed by one-way ANOVA, followed by
Newman-Keuls test as the post hoc test. Whenever needed
the data were analyzed by two-tailed unpaired Student’s 𝑡-
test. The differences were considered statistically significant
at 𝑝 < 0.05.
3. Results
3.1. Behavioral Tests
3.1.1. Open Field Test. We showed a 1.9-fold increase in
locomotor activity in the untreated ischemic group, as related
to the sham-operated one (SO, controls). The treatment of
ischemic groups with 𝜔3 (5 and 10mg/kg, p.o.) significantly
reversed the locomotor activity to values close to normality
(Figure 1(a)). A similar profile was seen with the rearing
behavior (Figure 1(b)). These effects were reversed after 𝜔3
treatments and, in both cases, the values were even lower than
those of the sham-operated group.
3.1.2.MorrisWaterMaze Test. We showed a significant 2-fold
increase in the time to find the platform after ischemia, as
related to controls (SO), indicating an impairment of spatial
learning and hipocampal dysfunction. On the other hand,
the repeated treatment of ischemic groups with 𝜔3 (5 and
10mg/kg), for 7 days, completely reversed the effects, showing
an improvement on spatial memory due to 𝜔3 treatments
(Figure 2).
3.2. Neurochemical Determinations
3.2.1. Dopamine (DA), DOPAC, and NE Determinations in
Rat Brain Striatum. Our results showed that brain ischemia
decreases in 37% DA levels, as related to controls (SO)
(Figure 3(a)). On the other hand, DA values returned to
normality (and similarity to those of the SO group), in the
ischemic group treated for 7 days with 𝜔3 (5 and 10mg/kg,
p.o.). Similar results were observedwithDOPACwhere a 26%
decrease was seen in the ischemic untreated group, as related
to controls (SO). In both cases, the values in the ischemic
group after 𝜔3 treatments (Figure 3(b)) returned to those
shown by the SO group. Surprisingly, a 9-fold increase in
NE contents, as related to the SO group, was observed in the
untreated ischemic group. NE levels returned to values even
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Figure 1: Evaluations of the number of crossing (a) and rearing (b) behaviors by the open field test. The columns represent means ± SEM
(number of crossings/5min) from SO and rats subjected to cerebral ischemia untreated or after oral treatments with 𝜔3, at the doses of 5 and
10mg/kg (number of animals per group: SO = 27; ISC = 35; ISC + 𝜔3 (5) = 14; ISC + 𝜔3 (10) = 17). (a) (A) versus SO, q = 6.591∗∗∗; (B) versus
ISC + 𝜔3 (5), q = 8.916∗∗∗; (C) versus ISC + 𝜔3 (10), q = 8.288∗∗∗; (D) versus SO, q = 3.435∗. (b) (A) versus SO, q = 5.533∗∗∗; (B) versus ISC
+ 𝜔3 (5), q = 6.808∗∗∗; (C) versus ISC + 𝜔3 (10), q = 7.246∗∗∗ (one-way ANOVA and Newman-Keuls test as the post hoc test).
A, B, C
0
10
20
30
Ti
m
e t
o 
fin
d 
th
e p
la
tfo
rm
 (s
)
SO ISC ISC + 𝜔3 (5) ISC + 𝜔3 (10)
Figure 2: Evaluation of the spatial memory by the water maze
test. The columns represent means ± SEM of the time (s) to find
the platform. The studied groups were SO and ischemic animals
untreated or after oral treatments with 𝜔3, at the doses of 5 and
10mg/kg (number of animals per group: SO = 28; ISC = 27; ISC +𝜔3
(5) = 14; ISC + 𝜔3 (10) = 14). (A) versus SO, q = 5.159∗∗; (B) versus
𝜔3 (5), q = 4.016∗; (C) versus𝜔3 (10), q = 3.897∗∗ (one-way ANOVA
and Newman-Keuls test as the post hoc test).
lower than those of the SO group, in ischemic animals after
𝜔3 treatments with the doses of 5 and 10mg/kg (Figure 3(c)).
3.3. Histological and Immunohistochemistry Assays
3.3.1. TTC Staining in the Hippocampus. The ischemic group
(ISC) showed a 69% decrease in TTC staining as related
to the SO group. This decrease was of only 13% in the
ischemic group after 𝜔3 treatment with the dose of 10mg/kg
(ISC + 𝜔3 (10)). On the other hand, no significant differences
were observed in the ISC group (ISC) without and after
treatment with 𝜔3 at the dose of 5mg/kg (ISC + 𝜔3 (5))
(Figure 4).
3.3.2. Fluoro-Jade Staining in the Hippocampus. A greater
number of fluorescent cells were observed in the CA1 hip-
pocampal subfield of the untreated ischemic group, indicat-
ing neuronal degeneration. This change is quantified by the
Image J software as a decrease (50%) in optical density, as
related to the SO group whose neurons appear darker. A
similar picture was observed in the CA3 area (51% decrease)
and in the dentate gyrus (56% decrease). In all cases, these
alterations were completely reversed after 𝜔3 treatments
(Figure 5).
3.3.3. Immunohistochemistry for TNF-Alpha, COX-2, and
iNOS in Hippocampus and Temporal Cortex. The immuno-
histochemistry data for TNF-alpha showed a higher number
of immunopositive cells in CA1, CA3, and dentate gyrus
areas in the ischemic group (ISC) as related to the SO
group. The effects were much more intense in the CA1 (313-
fold increase), followed by DG (30-fold increase) and CA3
(14-fold increase) areas. In all cases, these changes were
significantly decreased after 𝜔3 treatments (Figure 6).
Figure 7 shows representative photomicrographs for
COX-2 immunohistochemistry assays in the dentate gyrus
(DG) and hilus.While increases of 6- and 5-foldwere demon-
strated in the DG and hilus ischemic groups, respectively,
these effects were significantly reduced to similar values in
both areas after 𝜔3 treatments. Increases around 3.9-fold
in the iNOS immunoreactivity were detected in the CA3
area from ischemic groups as related to the SO group. The
effects were reduced to values even lower than those from
the SO group after treatments with 𝜔3 at the dose of 5mg/kg
(Figure 8).
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Figure 3: Evaluation of 𝜔3 treatments at the doses of 5 and 10mg/kg on the striatal contents of DA (a), DOPAC (b), and NE (c), in rats
subjected to brain ischemia and reperfusion for 7 days. The numbers of animals per group were the following: for DA, SO = 14, ISC = 9, ISC
+ 𝜔3 (5) = 19, and ISC + 𝜔3 (10) = 15; for DOPAC, SO = 14, ISC = 11, ISC + 𝜔3 (5) = 15, and ISC + 𝜔3 (10) = 14; for NE, SO = 8, ISC = 10, ISC
+ 𝜔3 (5) = 8, and ISC + 𝜔3 (10) = 6. The columns represent means ± SEM and the groups are sham-operated (SO); ischemic (ISC) untreated;
and ischemic after 𝜔3 treatments for 7 days. DA: (A) versus SO, q = 3.830∗∗; (B) versus 𝜔3 (5), q = 5.145∗∗; (C) versus 𝜔3 (10), q = 4.570∗∗.
DOPAC: (A) versus SO, t = 2.484, df = 23; (B) versus𝜔3 (5), q = 4.707∗∗; (C) versus𝜔3 (10), t = 2.085, df = 23. NE: (A) versus SO, q = 16.52∗∗∗;
(B) versus 𝜔3 (2.5), q = 18.79∗∗∗; (C) versus 𝜔3 (5), q = 17.09∗∗∗ (one-way ANOVA and Newman-Keuls test as the post hoc test).
4. Discussion
Global cerebral ischemia in rodents is characterized mor-
phologically by a selective neuronal damage, particularly in
the hippocampus, but also in the striatum and cortex [22].
The resultant damage to vulnerable cells, notably in the CA1
and hilar hippocampal fields, is frequently associated with
memory deficits [23]. The most common model for global
cerebral ischemia in rodents uses brain ischemia associated
with hypotension [24], which results in higher brain damage
mainly in the hippocampus. However, in the present work
we used the common carotids occlusion for 30min without
hypotension, which has been shown to cause alterations in
hippocampal CA1 neurons [25].
Furthermore, animal studies particularly in rodents indi-
cate that long chain 𝜔3 fatty acids play a role in behavioral
and cognitive functions. Chronic𝜔3 fatty acids deficiency has
been shown to increase anxiety in rodents, particularly under
stressful conditions [26–28]. It has been demonstrated that
a decreased content of docosahexaenoic acid (DHA), a long
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fluorescence to Fluoro-Jade) in hippocampus and cortex. The effects in CA1 and CA3 and DG are represented by photomicrographs and
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Figure 6: 𝜔3 treatments of ischemic animals (3 animals per group) reduced the immunostaining for TNF-alpha, mainly in CA1 and CA3
hippocampal subfields and in the dentate gyrus (DG). Representative photomicrographs and quantitative measurements performed with the
Image J software from 3 to 5 fields. The groups are SO, untreated ischemic (ISC) and ischemic after 𝜔3 treatments (5 and 10mg/kg, 7 days).
CA1: (A) versus SO, q = 41.76∗∗∗; (B) versus ISC + 𝜔3 (5), q = 40.44∗∗∗; (C) versus ISC + 𝜔3 (10), q = 40.63∗∗∗. CA3: (A) versus SO, q =
32.86
∗∗∗; (B) versus ISC + 𝜔3 (5), q = 7.494∗∗∗; (C) versus ISC + 𝜔3 (10), q = 33.31∗∗∗; (D) versus SO, q = 7.494∗∗∗; (E) versus ISC + 𝜔3 (10),
q = 23.91∗∗∗. DG: (A) versus SO, q = 30.26∗∗∗; (B) versus ISC + 𝜔3 (10), q = 27.34∗∗∗ (one-way ANOVA and Newman-Keuls test as the post
hoc test).
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The groups are untreated ischemic (ISC) and ischemic after treatments with 𝜔3 (2.5 and 10mg/kg, 7 days). DG: (A) versus SO, q = 14.88∗∗∗;
(B) versus ISC + 𝜔3 (2.5), q = 7.135∗∗∗; (C) versus ISC + 𝜔3 (10), q = 4.979∗∗. Hilus: (A) versus SO, q = 13.95∗∗∗; (B) versus ISC + 𝜔3
(2.5), q = 7.418∗∗∗; (C) versus ISC + 𝜔3 (10), q = 6.943∗∗∗; (D) versus SO, q = 6.527∗∗∗; (E) versus SO, q = 7.003∗∗∗ (one-way ANOVA and
Newman-Keuls test as the post hoc test).
chain polyunsaturated fatty acid of the 𝜔3 series, is accom-
panied by anxiety and learning and memory impairments
that have been associated with changes in neurotransmission
processes [10].
Most of the literature data deal with animals chronically
submitted to 𝜔3 supplemented diet [29–33] or 𝜔3 high
dose, as seen in preclinical [34, 35] and clinical studies
as well [36]. As far as we know, ours is the first study
dealing with 𝜔3 administration for a short period and at
a lower dose range. We focused on behavioral changes,
determinations of striatal monoamines, and immunohisto-
chemistry assays in the hippocampus of animals submitted
to global brain ischemia untreated or treated with 𝜔3 fatty
acids.
The majority of studies performed with 𝜔3 describe its
dietary effects after 3 to 5 weeks [37–39] and very few [40]
use a short-term treatment (1 week). While this last study
showed an effect of 𝜔3 on lipid metabolism after short-
term treatment, others [41] observed no effect after the 𝜔3
treatment for 2 weeks on the scopolamine-induced amnesia.
In the present study we demonstrated that 𝜔3 at lower doses
can be effective after daily administration by gavage to rats
and well absorbed after its emulsification as already shown
[42] and in an empty stomach.This short-term effect of lower
Journal of Nutrition and Metabolism 9
A, B
C
0
50000
100000
150000
200000
250000
iN
O
S 
(o
pt
ic
al
 d
en
sit
y)
ISCSO
iNOS (CA3, ×100)
SO ISC ISC + 𝜔3 (5)
ISC + 𝜔3 (5)
Figure 8:𝜔3 treatments (3 animals per group) reduced the immunostaining for iNOSmainly in theCA3hippocampal subfield. Representative
photomicrographs andmeasurements performed with the Image J software, from 3 to 5 fields.The groups are sham-operated (SO), untreated
ischemic (ISC), and ischemic after 𝜔3 treatment (5mg/kg, 7 days). (A) versus SO, q = 16.03∗∗∗; (B) versus ISC + 𝜔3 (5), q = 19.49∗∗∗; (C)
versus SO, q = 3.456∗ (one-way ANOVA and Newman-Keuls test as the post hoc test).
doses of𝜔3 was clearly observed by us after the TTC staining,
a reliable method for the detection of brain ischemic areas in
the rat [21].
In the open field test, we showed that after global
brain ischemia the animals presented not only an increased
locomotor activity, but also an increased number of rearing
behaviors, as related to controls (SO). On the other hand, the
treatment of ischemic groups with 𝜔3 significantly decreased
all these behavioral parameters to values close to those of
controls. Brain ischemia is known to increase locomotor
activity and anxiety [43–47] and the degree of hippocampal
damage has been positively correlated with the increase in
motor activity.
Our data showed that brain ischemia significantly
impaired spatial memory, and this effect was completely
reversed after 𝜔3 treatments. Evidences indicate that tran-
sient global ischemia may lead to severe impairments in
learning and memory [48–50]. The pyramidal CA1 neu-
rons of the hippocampus are critically involved in spatial
learning and memory and are also especially vulnerable to
cerebral ischemia. The transient global cerebral ischemia
model results in neurodegeneration, known to induce both
hippocampal neuronal loss and learning deficits in rats [48,
50, 51]. Reduction of memory deficits by PUFA, after global
ischemia, has been already observed by others [30, 34, 52].
However, in most of these data, the animals were chronically
subjected to a rich-in-𝜔3 fatty acids diet, while in the present
study the animals were orally given lower doses of 𝜔3, for a
short period of time.
We also showed a 37% reduction in DA levels in
the striata of ischemic rats, as related to the SO group.
On the other hand, these effects were completely reverted
after 𝜔3 treatments and a similar picture was noticed in
DOPAC levels. Ischemic conditions can induce the release of
brain neurotransmitters. Earlier studies showed that the DA
metabolism is significantly altered during and after ischemia
in the rabbit retina [53]. On the other hand, biochemical
consequences of ischemia in the hippocampus, cortex, and
striatum have been object of much attention, because these
brain structures are particularly vulnerable to ischemia [54].
The extracellular levels of DA have been shown to increase
drastically, immediately after ischemia. This increase is fol-
lowed by a great decrease, probably reflecting that the release
of DA is not compensated by an increased synthesis of this
neurotransmitter [55–60].
Evidences indicate that DA release exerts an important
role in the striatal damage observed after ischemia. As a
matter of fact, the depletion of DA by alpha-methyltyrosine
or 6-OHDA before the ischemic process reduces the degree
of neuronal damage [61–63], using an experimental model
similar to ours, showing by microdialysis that the extracel-
lular concentrations of DA increased abruptly, around 3min
after the ischemic insult, reaching a maximum value between
20 and 40min after the insult and decreasing subsequently.
These authors concluded that, during ischemia, the great
increase in DA concentrations occurs probably as a result of
energy failure in cellular membranes. Then, the DA release
could be the cause of the neuronal damage, associated with
brain ischemia.
In our study, it is possible that, because DA determina-
tions in the striatum were carried out 7 days after ischemia,
this brain tissue was already partly recovered. Despite that,
our results showed a partial recovery of the alterations
in DA levels in the ischemic groups after 𝜔3 treatments.
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Others [7] showed that𝜔3 fatty acids present neuroprotective
properties, exerting benefits on cognitive functions, neurode-
generative diseases, and brain ischemia.
Evidences [64] have indicated the effects of a diet which
was deficient in alpha-linolenic acid, precursor of long
chains unsaturated fatty acids as 𝜔3, on the dopaminergic
neurotransmission in the core of the rat nucleus accumbens.
These in vivo microdialysis experiments showed increased
basal levels of dopamine and their metabolites (DOPAC and
HVA), in rats subjected to a fatty-acid-deficient diet, as com-
pared to controls, indicating alterations in the dopaminergic
neurotransmission in the nucleus accumbens.
For the assessment of neuronal degeneration, we used the
staining with Fluoro-Jade which is a fluorescein derivative
that specifically binds to degenerating neurons. Fluoro-Jade
stains cell bodies, dendrites, axons, and their terminals but
does not stain healthy neurons [65]. We showed a high
number of degenerating neurons in the CA1, CA3, dentate
gyrus, and temporal cortex from untreated ischemic rats,
and this profile was completely reversed after 𝜔3 treat-
ments, towards that of SO (controls), indicating the drug
neuroprotective effects. Interestingly, Fluoro-Jade staining
demonstrating neuronal damage was shown in some brain
areas of animals submitted to PUFAs dietary restriction [66],
corroborating with our findings.
While PUFAs are known to present brain immunomod-
ulatory properties, n-3 PUFAs are able to reduce inflamma-
tion and n-6 PUFAs are more proinflammatory [67]. These
authors showed that the central n-3 PUFA increasemodulates
the brain innate immune system, leading to the protection
against LPS-induced proinflammatory cytokine production
and spatialmemory impairment, in transgenicmice. Recently
[68], 𝜔3 was shown to reduce cytokine-induced expression
of proatherogenic and proinflammatory proteins, in human
endothelial cells, and these properties may contribute to the
antiatherogenic and anti-inflammatory effects of n-3 PUFAs.
In the present study, the treatment of ischemic animals
with 𝜔3 drastically decreased immunoreactivity for TNF-
alpha in the hippocampus and temporal cortex. A previous
work [69] demonstrated that 𝜔3 pretreatments significantly
attenuated LPS-stimulated TNF-alpha production. Others
[70] showed that the inhibition by 𝜔3 of proinflammatory
cytokines as TNF-alpha, in murine macrophages, is in
part mediated by the inactivation of NF-kappaB signaling.
Besides, Nielsen et al., 2005 [71], observed that 𝜔3 fatty
acids were able to inhibit the increase in proinflammatory
cytokines, in patients with Crohn’s disease. 𝜔3 fatty acids
are known to affect immune response, partly by influencing
cytokine secretion [72].
Furthermore, we also showed that the treatments with 𝜔3
of ischemic animals significantly decreased COX-2 and iNOS
immunoreactivity in hippocampal brain areas. Evidences
indicate that 𝜔3 fatty acids dampen inflammation, through
multiple pathways, and directly or indirectly suppress the
activity of nuclear transcription factors, as NF-kappaB, and
reduce the production of proinflammatory enzymes and
cytokines, including COX-2, TNF-alpha, and IL-1B [73]. NF-
kappaB is one of the most important transcription factors
involved in inflammatory response and upregulation of gene
encoding of inflammatory cytokines, adhesion molecules,
andCOX-2. Evidences indicated that𝜔3 decreases expression
of adhesion molecules and production of inflammatory
cytokines and COX-2 metabolites, and a common mecha-
nism would be the impact on the NFkB system [74]. This
could well be the way 𝜔3 is acting in our study.
Besides decreasing COX-2 immunostaining, 𝜔3 attenu-
ates hippocampal iNOS immunoreactivity. It has been shown
that a diet rich in 𝜔3 fatty acids decreases eNOS and iNOS
in the diabetic kidney [75]. Interestingly, the attenuation of
iNOS in LPS-stimulated macrophages by 𝜔3 was shown to
be independent of COX-2 derived PGE2, contradicting the
hypothesis that the decrease in NO production associated
with 𝜔3 treatments occurs through a COX-2 derived PGE2
dependent mechanism [76]. The expression of iNOS is one
direct consequence of inflammatory processes [77]. One
important step during inflammation is leukocyte infiltration,
mainly controlled by chemokines. The production of these
chemokines is positively or negatively regulated by iNOS-
derived NO [78]. Furthermore, a clinical study demonstrated
that fish oil decreased serum levels of TNF-alpha, IL-
1beta, IL-6, and nitric oxide metabolites in multiple sclerosis
patients treated with IFN-1beta [79].
5. Conclusion
𝜔3 fatty acids by their anti-inflammatory and antioxidant
properties that contribute to the neuroprotective property
might be a therapeutic target to be pursued for the prevention
or treatment of inflammation-related diseases. 𝜔3 deficiency
increases the brain’s vulnerability, representing an important
risk factor for the development of neuropathologies [80]. Fur-
thermore, understanding the precise roles of 𝜔3 fatty acids,
as a possible disease modifier, will permit the development of
new therapies for neurological diseases.
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